AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15172083
Drug: Oral oestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oestradiol therapy for 12 weeks
Trial: 12352236
Drug: 0.4 percent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 percent nitroglycerin ointment applied twice or three times per day
Trial: 9815340
Drug: Scopolamine Transdermal
RxNorm normalized name: scopolamine Transdermal System
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Scopolamine Transdermal Therapeutic System (TTS)
Trial: 26643558
Drug: Routine antenatal
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine antenatal and postnatal home-based care plus screening and treatment for abnormal vaginal flora (AVF) and urinary tract infection (UTI).
Trial: 18637554
Drug: Intralesional steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional steroid (diluted Triamcinolone acetonide)
Trial: 18637554
Drug: Silicone-gel sheeting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone-gel sheeting
Trial: 12660407
Drug: D-ribose (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-ribose (10 g/d for 5 d)
Trial: 12660407
Drug: Dextrose placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose placebo (5 g, twice daily)
Trial: 1838693
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg cilazapril
Trial: 1279292
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg cilazapril + 0.5 mg cyclopenthiazide (CPTZ)
Trial: 1279292
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg cilazapril + 0.5 mg CPTZ
Trial: 1279292
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg cilazapril alone
Trial: 2988158
Drug: suloctidil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suloctidil (200 mg t.i.d.)
Trial: 22083263
Drug: Right half‐field
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Right half‐field patch treatment (n=10) for approximately 8 hours a day for 15 consecutive days
Trial: 20395128
Drug: Carboplatin AUC
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC 7 every 3 weeks followed by concurrent paclitaxel 175 mg/m2 (day 1) and gemcitabine 1000 mg/m2 (days 1 and 8) every 3 weeks
Trial: 20395128
Drug: Sequential schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential schedule with weekly paclitaxel
Trial: 16037481
Drug: Programa de
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programa de Entrenamiento para el Desarrollo de Aptitudes para Latinos (PEDAL) group therapy
Trial: 10567776
Drug: Isoniazid (INH,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoniazid (INH, 300 mg once daily) plus sulphadoxine-pyrimethamine (S, 500 mg/P, 25 mg once weekly)
Trial: 7867175
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin patches
Trial: 428710
Drug: Chenodeoxycholic acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodeoxycholic acid (CDCA), 750 mg/day during weight maintenance (1st month) and weight reduction (2nd month)
Trial: 428710
Drug: Bile acid
RxNorm normalized name: Bile acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bile acid preparations (CDCA and Bilron) administered randomly during weight reduction
Trial: 22111802
Drug: standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard care therapy over seven-days a week
Trial: 22111802
Drug: group circuit
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: group circuit class therapy over five-days a week
Trial: 22111802
Drug: usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: usual care therapy over five-days a week
Trial: 18154473
Drug: Nelfinavir 1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nelfinavir 1250 mg every 12 hours for 4 days
Trial: 18154473
Drug: Nelfinavir 1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nelfinavir 1250 mg every 12 hours and omeprazole 40 mg every 24 hours for 4 days
Trial: 18074761
Drug: Mistletoe extracts
RxNorm normalized name: MISTLETOE EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mistletoe extracts Iscador (therapy suggested by attending physician)
Trial: 18074761
Drug: Mistletoe extracts
RxNorm normalized name: MISTLETOE EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mistletoe extracts Iscador (therapy)
Trial: 10703459
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (HP, HC, HF, NS)
Trial: 2580155
Drug: Atenolol (cumulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (cumulative doses of 1-8 mg)
Trial: 2580155
Drug: Acebutolol (cumulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol (cumulative doses of 10-80 mg)
Trial: 27958381
Drug: Buprenorphine/naloxone (Suboxone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/naloxone (Suboxone) treatment
Trial: 24733277
Drug: Collaborative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative care (CC) intervention for depression and anxiety disorders (n=92)
Trial: 22445052
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy intervention
Trial: 18612787
Drug: DDD‐FP (5‐FU,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDD‐FP (5‐FU, 320 mg/m² daily for 21 days; CDDP, 3.5 mg/m² daily for 21 days) followed by oral 5‐FU (200 mg/body daily for 2 years)
Trial: 18612787
Drug: Oral 5‐FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 5‐FU therapy (200 mg/body daily for 2 years)
Trial: 12052597
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol (100 microg every 3-4 hours, with possible increase to 200 microg)
Trial: 10672723
Drug: Amizon (anti-inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amizon (anti-inflammatory interferon-inducing drug)
Trial: 8754965
Drug: Systemic steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic steroids (prednisone)
Trial: 8754965
Drug: Inhaled steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled steroids in typical dose
Trial: 1654753
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of 0.5% bupivacaine (pH, 5.58 +/‐ 0.12)
Trial: 1654753
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of 0.5% bupivacaine + 0.6 mL of 1.4% bicarbonate (pH, 6.53 +/‐ 0.06)
Trial: 7046412
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (150 mg/m2 daily in three divided doses)
Trial: 3511184
Drug: Tamoxifen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (10 mg twice daily)
Trial: 24533507
Drug: Topical valproic
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical valproic acid (sodium valproate, 8.3%)
Trial: 17972591
Drug: Inhaled corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroid and as-needed beta-agonist
Trial: 17972591
Drug: Dongchong xiacao
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dongchong xiacao capsule plus inhaled corticosteroid and as-needed beta-agonist
Trial: 14760514
Drug: Lecithin (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lecithin (1.6 g/day)
Trial: 14760514
Drug: Carnitine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carnitine (500 mg/day)
Trial: 7805564
Drug: Hyperfractionated irradiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated irradiation (HF) with 1.15‐1.25Gy per fraction, twice daily, total doses of 69.6 +/- 2.1Gy
Trial: 7805564
Drug: Conventional irradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional irradiation (CF) with 1.8‐2.0Gy per fraction, once a day, total doses of 63.9 +/- 1.1Gy
Trial: 31074205
Drug: Canagliflozin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin (100 mg/day)
Trial: 30241913
Drug: Manual lymph
RxNorm normalized name: Bos taurus lymph preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual lymph drainage (MLD) in addition to information and exercise therapy
Trial: 16736081
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of harm reduction and social norming messages
Trial: 7761019
Drug: Betamethasone 0.1
RxNorm normalized name: betamethasone 0.122 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone 0.1 mg/kg administered 10 min after continuous infusion of vecuronium
Trial: 7761019
Drug: Vecuronium 0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.08 mg/kg bolus followed by continuous infusion of 0.4‐0.5 micrograms/kg/min
Trial: 3288070
Drug: Aspirin 500
RxNorm normalized name: aspirin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 500 mg tid for seven days
Trial: 31965579
Drug: Obeticholic acid
RxNorm normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Obeticholic acid (OCA) 25 mg orally once daily
Trial: 7955939
Drug: Caffeine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (4 mg kg‐1)
Trial: 23963274
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (2 mg/kg/day for 60 days)
Trial: 21598858
Drug: Analogy-guided learning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analogy-guided learning activities incorporated into weekly group discussions, reflective journal writing, and questioning with clinical faculty.
Trial: 19090531
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy (BT) including Individualized Sleep Promotion Plan (ISPP) with modified stimulus control, modified sleep restriction, relaxation therapy, and sleep hygiene.
Trial: 16720830
Drug: Hematide 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hematide 0.1 mg/kg
Trial: 15464488
Drug: Papaverine injection
RxNorm normalized name: papaverine Injection
DrugBank: Papaverine (DB01113)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Papaverine injection before harvest (Group 2)
Trial: 11779325
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment and observation
Trial: 9025770
Drug: 5-fluorouracil (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil (375 mg/m2 per day) and leucovorin (200 mg/m2 per day) administered intravenously (days 1-5) with levamisole (30 to 470 mg/m2 per day) administered orally (days 1-3 and 15-17)
Trial: 8513037
Drug: Late melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late melatonin (5 mg for 5 days after 3 days of placebo)
Trial: 8513037
Drug: Early melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early melatonin (5 mg started 3 days prior to arrival until 5 days after return home)
Trial: 23722592
Drug: Recombinant adenoviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant adenoviral human p53 gene therapy (rAd‐p53) with radiotherapy (60 Gy)
Trial: 12938264
Drug: 5-FU-based chemotherapy
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU-based chemotherapy
Trial: 12938264
Drug: 5-FU or
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU or other cytotoxic agent alone
Trial: 8783704
Drug: Inappropriate antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inappropriate antimicrobial treatment
Trial: 1385761
Drug: Toremifene 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene 200 mg/m2 p.o. daily
Trial: 1385761
Drug: Toremifene 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene 300 mg/m2 p.o. daily
Trial: 1385761
Drug: Toremifene 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene 400 mg/m2 p.o. daily
Trial: 1385761
Drug: Toremifene (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene (all doses)
Trial: 1385761
Drug: Toremifene pharmacokinetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene pharmacokinetics
Trial: 30663156
Drug: Diet and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet and exercise intervention (1-h weekly diet sessions and 75-min bi-weekly physical activity sessions)
Trial: 29746725
Drug: DS-2969b (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-2969b (6 mg, 20 mg, 60 mg, 200 mg, 400 mg, 600 mg)
Trial: 29746725
Drug: DS-2969b (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-2969b (60 mg or higher)
Trial: 26881019
Drug: Increased urinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased urinary total polyphenol excretion (TPE)
Trial: 25257875
Drug: Insulin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (5 mU·kg(‐1)·min(‐1))
Trial: 15127089
Drug: Vegetable juice
RxNorm normalized name: Vegetable Juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vegetable juice supplementation (one can daily)
Trial: 15127089
Drug: Placebo (orange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (orange soda, placebo pill daily)
Trial: 11779889
Drug: Aspirin (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (81 to 325 mg per day)
Trial: 2062511
Drug: Aspirin (650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (650 mg per day)
Trial: 11779889
Drug: Aspirin (975
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (975 to 1300 mg per day)
Trial: 11779889
Drug: No aspirin
RxNorm normalized name: XS No Aspirin PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No aspirin (no antithrombotic drugs or ticlopidine)
Trial: 9842977
Drug: Amoxicillin 500
RxNorm normalized name: amoxicillin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 500 mg x 2
Trial: 9842977
Drug: Cefadroxil 500
RxNorm normalized name: cefadroxil 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefadroxil 500 mg x 2
Trial: 9842977
Drug: Cefixime 200
RxNorm normalized name: cefixime 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime 200 mg with Niflumic acid (250 mg)
Trial: 9842977
Drug: Cefixime 200
RxNorm normalized name: cefixime 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime 200 mg with Paracetamol (500 mg)
Trial: 7734464
Drug: Matrix outpatient
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matrix outpatient stimulant treatment
Trial: 2477936
Drug: Flutamide (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide (750 mg/d)
Trial: 31560137
Drug: Benazepril (0.5‐1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril (0.5‐1.0 mg/kg) administered PO once daily for up to 2 years
Trial: 31560137
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered PO once daily for up to 2 years
Trial: 28599199
Drug: 1L normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1L normal saline (NS) administered as a rapid infusion over 30 min
Trial: 28599199
Drug: 1L normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1L normal saline (NS) administered as a slow infusion over 120 min
Trial: 25557740
Drug: Higher cumulative
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher cumulative bortezomib dose (≥39 mg/m²)
Trial: 25557740
Drug: Lower cumulative
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower cumulative bortezomib dose (<39 mg/m²)
Trial: 25557740
Drug: Higher cumulative
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher cumulative bortezomib dose (≥39 mg/m²) after landmark analysis
Trial: 25557740
Drug: Lower cumulative
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower cumulative bortezomib dose (<39 mg/m²) after landmark analysis
Trial: 19863282
Drug: MDIS (metered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDIS (metered dose inhaler with spacer device)
Trial: 19863282
Drug: Standard nebulizer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard nebulizer therapy
Trial: 16923091
Drug: High-dose insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose insulin treatment (short-acting insulin 1 IU/kg/h with 30% glucose 1.5 ml/kg/h)
Trial: 16923091
Drug: High-dose insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose insulin treatment and Control treatment
Trial: 14579657
Drug: 0.05% oxymetazoline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% oxymetazoline nasal spray (2 sprays, 0.1 ml/spray) 3 times daily for 4 weeks
Trial: 14579657
Drug: 0.05% oxymetazoline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% oxymetazoline nasal spray
Trial: 27830923
Drug: Routine treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatments (Control group)
Trial: 18163056
Drug: Hyperbaric oxygenation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygenation therapy
Trial: 9808685
Drug: Finasteride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (5 mg once daily for 10 days) with 10 mg/kg tirilazad mesylate orally
Trial: 9808685
Drug: Finasteride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (5 mg once daily for 10 days) with 2 mg/kg tirilazad mesylate i.v.
Trial: 7851350
Drug: Propofol (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (continuous intravenous infusion starting dose 3 mg kg‐1 h‐1)
Trial: 1096908
Drug: Etidocaine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidocaine at 10 mg/min
Trial: 1096908
Drug: Etidocaine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidocaine at 20 mg/min
Trial: 1096908
Drug: Lignocaine at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine at 20 mg/min
Trial: 28535819
Drug: Ibuprofen (overt)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen (overt)
Trial: 28535819
Drug: Paracetamol (overt)
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol (overt)
Trial: 16719026
Drug: Static positional
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Static positional stretches of the stroke‐affected shoulder twice daily and positioned the stroke‐affected upper limb in an armrest support at all other times when seated.
Trial: 16719026
Drug: Treatment group.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group.
Trial: 15232326
Drug: Olanzapine (OLZ)
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine (OLZ) 5 to 20 mg/d
Trial: 15232326
Drug: Olanzapine/fluoxetine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine/fluoxetine combination (OFC) 5 to 20 mg/d olanzapine + 20 to 80 mg/d fluoxetine
Trial: 11547961
Drug: Steroid-containing drug
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-containing drug delivery system (DDS)
Trial: 11547961
Drug: Topical chloramphenicol
RxNorm normalized name: chloramphenicol Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical chloramphenicol eyedrops
Trial: 8335134
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of zinc supplementation during pregnancy
Trial: 24797300
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (VPA) with chemotherapy (idarubicin, cytarabine, and all-trans retinoic acid)
Trial: 16845131
Drug: L-IVRA group
RxNorm normalized name: Ivra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-IVRA group (lidocaine 0.5% with lornoxicam)
Trial: 16845131
Drug: L-IV group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-IV group (intravenous lornoxicam and IVRA lidocaine 0.5%)
Trial: 1928686
Drug: Propofol (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1.6 mg/kg to 2.6 mg/kg in 0.2 mg/kg increments)
Trial: 1928686
Drug: Propofol mixed
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol mixed with lignocaine (0.5 mg/ml)
Trial: 30932955
Drug: MGN1703 (TLR9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MGN1703 (TLR9 agonist); 60 mg × 2 weekly for 24 weeks
Trial: 23138399
Drug: Milrinone (MR;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milrinone (MR; 0.5‐1 μg/kg/min)
Trial: 23138399
Drug: Levosimendan (LEVO;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (LEVO; 0.1‐0.2 μg/kg/min)